Healthcare Industry News: liver failure
News Release - August 2, 2007
Stem Cell Therapy International Acquires Exclusive Worldwide Rights to New, Anti-Rejection Stem Cell TechnologyTAMPA, FL--(Healthcare Sales & Marketing Network)--Aug 2, 2007 -- Stem Cell Therapy International, Inc. (OTC BB:SCII.OB ), a leading research and development company in the regenerative medicine field, announced today that it has acquired the exclusive worldwide rights to a new, U.S. Patent Pending anti-rejection umbilical cord blood stem cell technology. Calvin Cao, CEO of Stem Cell Therapy International and co-inventor of the new technology, explained why this new stem cell procedure is so important: "Stem cell treatments are transplants of cells, which is different than the transplant of entire organs such as the kidney or liver. In the case of organ transplants, many patients die each year because a 'matching' donor cannot be found in time. If a technology could be developed in which every organ was a 'match,' it would be a major achievement in medical science. This new method of transplanting umbilical cord stem cells that are considered compatible for anyone could, in some cases, actually replace costly and complicated organ transplants. Stem cell transplants are far simpler procedures in which stem cells are injected to stimulate the production of new cells in the affected organ."
This new technology gives Stem Cell Therapy International a large competitive advantage over other biotech companies. Mr. Cao explained the potential indications by saying, "Now that we have the exclusive right to this technology, any other company throughout the world that wishes to take advantage of this patent-pending process will have to pay Stem Cell Therapy International a royalty for each stem cell treatment they sell."
About the Inventors of the New, Anti-Rejection Stem Cell Technology
CALVIN CAO. This is the fourth stem cell-related technology invention of Calvin Cao. Mr. Cao is a seasoned entrepreneur and a founder or co-founder of five companies. As chief executive officer of Stem Cell Therapy International (SCTI), he is the driving force behind the strategy to make SCTI the dominant global company in the field of stem cell transplants and other newly develop cell therapies. After graduating from the University of South Florida in 1991, with a BSEE degree in electrical engineering, Mr. Cao launched Cao Computer Technology, Tampa, Florida. That company provided services for large businesses and universities as well as state and local governments. Mr. Cao managed that company successfully until 1996, when it merged with International Net Corp., Tampa, Florida, which is a worldwide distributor of IT products and other high-quality electronic products; a company of which Mr. Cao was also a co-founder. In 2004, Mr. Cao co-founded Vascular Relief Center Corp., the parent company of a chain of vascular clinics called Vein Associates, headquartered in Heathrow, Florida. Vein Associates specialized in the diagnosis and non-surgical treatment of hemorrhoids, varicose and spider veins using minimally invasive procedures. Vein Associates still continues to operate and is active in acquisitions of other similar clinics and businesses. In 2005, Mr. Cao founded SCTI and decided to dedicate his energies to working full time with Stem Cell Therapy International, Inc.
LIXIAN (JOHN) JIANG. This is the fourth invention of John Jiang. Mr. Jiang is a stem cell scientist who is recently completed the PhD requirements from the University of South Florida, which is located close to the offices of Stem Cell Therapy International in Tampa, Florida. Mr. Jiang has published approximately 58 original medical research articles and abstracts, including: 1. Lixian Jiang; Steve Poulos, Tanja Zigova, P. R. Sanberg, Keith R. Pnnypaker and A. E. Willing. Changes in cellular proliferation in the brain of Sprague-Dawley rats after stroke. Experimental Neurology, 175:439,2002 2. Lixian Jiang, A.E. Willing, M. Milliken, S. Poulos, J. Sanchez-Ramos, T. Zigova, S. Song, J. Chen, M. Chopp, and P. R. Sanberg. Intravenous or intracranial transplantation of umbilical cord mononuclear cells reduces hyperactivity in a rodent model of stroke. Experimental Neurology, 170:198,2001 3. Lixian Jiang, Mary Newman, Sameul Saporta, Ning Chen, Cyndy Davis Sanberg, Paul R. Sanberg, Alison E. Willing In vitro evidence for MIP-1alpha and MCP-1beta Regulation Systemically Delivered human umbilical cord blood migration into brain after stroke in rats. Stroke (in press 4. Lixian Jiang, Mary Newman, Sameul Saporta, Ning Chen, Cyndy Davis Sanberg, Paul R. Sanberg, Alison E. Willing. Human umbilical cord blood depress microglia inflammatory response in vitro. Journal of Neuroscience (In press) 5. Willing AE, Lixian J, Milliken M, Poulos S, Zigova T, Song S, Hart C, Sanchez-Ramos J, Sanberg PR. Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res. 2003 Aug 1; 73(3): 296-307. John Jiang is also a senior attorney from China and a Patent Agent in the US. He specializes in intellectual property law, China tax law and corporate law. He has worked in a number top specialty law firms before he joined SCTI in June of 2006. In addition John Jiang is employed in the capacity as Chief Operating Officer and Patent Trademark Counsel of the China Division of Stem Cell Therapy International, Inc.
About Stem Cell Therapy International
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading-edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company's website www.SCTIcorp.com
Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.
Source: Stem Cell Therapy International
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.